SIRPA and glioma: When we treated murine glioma cells with an anti-mouse-CD47 mAb (clone MIAP410) known to functionally inhibit murine CD47–SIRPα interactions5,12, we only observed a 10–20% increase in tumor cell phagocytosis by bone marrow (BM)-derived phagocytes (Fig. 1b).